Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial
Timo Vesikari,et al. for the PROTECT Study Group